👉🏻Excited to have co-authored this pan-cancer review of PARP inhibitor efficacy and safety in CA: A Cancer Journal for Clinicians ! Grateful to work alongside such a talented team. GU Cancer Research Program @HuntsmanCancer Huntsman Cancer Institute Neeraj Agarwal, MD, FASCO UT Southwestern Internal Medicine UTSW Internal Medicine Chiefs UTSW Hematology & Oncology

Is it time to re-classify urachal cancer as a GI rather than a GU malignancy? In npj Journals Precision Oncology, we show the genomic profile of this rare cancer is more similar to colorectal than bladder cancer. (1/2) Link: nature.com/articles/s4169…

Ab#104 ASCO #GU25 by Umang Swami👉bit.ly/3CIfFAy👉In pts with mHSPC #prostatecancer in Flatiron Health 👉Glad to report an improved utilization of intensified ADT in 77% of pts since January 2023👇GU Cancer Research Program @HuntsmanCancer OncoAlert UroToday.com PCF Science

#GU25 ⭐️ Full house for the final OS data of TALAPRO-2! Improved OS seen in BRCA-negative mCRPC patients. No additional safety signals reported. Presented by Neeraj Agarwal, MD, FASCO. #ProstateCancer #mCRPC GU Cancer Research Program @HuntsmanCancer Huntsman Cancer Institute Umang Swami, MD, MSCI, FASCO

Just in JCO Oncology Practice👉Challenges in the management of advanced #prostatecancer👉 Underutilization of life prolonging meds and genomic testing, high attrition of pts, and others👇bit.ly/3QIjDN0 Umang Swami Neeraj Agarwal, MD, FASCO OncoAlert UroToday.com GU Cancer Research Program @HuntsmanCancer

Just in JAMA Network Open👉Flatiron Health Real world Rx data from >8500 pts w/ mRCC #kidneycancer 👉After 2018, only 38% & 14% of pts received 2nd & 3rd line Rx respectively👇bit.ly/41H22dp Thanks to my mentors Umang Swami Sumanta K. Pal, MD, FASCO Neeraj Agarwal, MD, FASCO Cc OncoAlert UroToday.com

Thrilled to have matched University of Utah Department of Internal Medicine for my internal medicine residency training! Can't wait to get started! Utah IM CMRs Grateful for the terrific support of my family, friends, and mentors Neeraj Agarwal, MD, FASCO Umang Swami Benjamin L Maughan GU Cancer Research Program @HuntsmanCancer ! #Match2025

Real-world treatment patterns in #mHSPC in the US. Umang Swami, MD, MSCI, FASCO and Neeraj Agarwal, MD, FASCO Huntsman Cancer Institute discuss encouraging findings from a large retrospective study using the Flatiron Health database of 14,000 patients showing that ADT intensification therapies have risen dramatically

A novel west-African germline founder mutation in HOXB13 (p.X285Kext) increases risk of high-grade prostate cancer but also enhances sensitivity to hormonal therapy. Congrats to PCF-funded Mayuko Kanayama 👏 Neeraj Agarwal, MD, FASCO Prostate Cancer Foundation UroToday.com Ed Esplin, MD, PhD nature.com/articles/s4139…

🧬 BRCA mutations = worse prognosis in all mHSPC, regardless of disease volume or treatment. Risk stratification should include genomics. Congratulations David and all team. 👏👏👏 David Olmos Elena Castro Daniel Castellano Annals of Oncology Tom Powles Advanced Prostate Cancer Consensus Conference OncoAlert

1/5 #RenalMedullaryCarcinoma (RMC) is a lethal #KidneyCancer in young people with #SickleCellTrait (SCT). Our new prospective study Urologic Oncology asks: does VIGOROUS exercise raise risk? 👉pubmed.ncbi.nlm.nih.gov/40617795/ #MsaouelLab

Hats off to Regina Barragan-Carrillo who (w Zeynep Zengin Yale Internal Medicine) put together a beautiful overview of #microbiome modulation for the treatment of #solidtumors in Journal of Clinical Oncology. Citing work from innovative #scientists & #trialists in the field like #Routy, #ElKrief, lisaderosa, #Zitvogel,

ASCO Thank you, ASCO, for this great honor. Truly humbled to receive the FASCO designation and proud to be part of a community so deeply committed to advancing cancer care and supporting one another. Grateful to serve alongside such inspiring colleagues. #FASCO #oncology

Safety and Efficacy of Tarlatamab in patients with Neuroendocrine Prostate Cancer: Results from the Phase 1b DeLLpro-300 Study | Clinical Cancer Research | American Association for Cancer Research aacrjournals.org/clincancerres/…

Congrats Sia Daneshmand, M.D. Andrea Necchi 👉 Striking results in Journal of Clinical Oncology from Ph2b #SunRISe-1 trial in pts w/BCG-unresponsive high-risk NMIBC #bladdercancer treated w/ TAR-200 monoRx ➡️~83% CR, with >2 yrs median response, ~13% Grade ≥3 TRAEs ➡️ tinyurl.com/4t2ywny9 UroToday.com

👉🏻Just in Journal of Clinical Oncology: We explore how biomarker-driven, rational combos may unlock ICI potential in mCRPC #prostatecancer 👇🏻 Plus data showing responses in MMRD, HRD, or high inflammatory infiltrates Neeraj Agarwal, MD, FASCO Tian Zhang, MD, MHS, FASCO (@tiansterzhangmd.bsky) Zeynep Irem Ozay, MD OncoAlert bit.ly/3UHqw2W

Exploratory biomarker analyses of adjuvant #nivolumab in urothelial carcinoma from #CheckMate274 trial are out in Nature Medicine Matt Galsky | 1. Pre-existing immune infiltration and T-cell infiltration is prognostic and predictive of adj Nivo benefit 2. Composite model

JUST IN: (+) Phase 3 KEYNOTE-905 trial in cisplatin-ineligible patients with muscle-invasive bladder cancer (MIBC): EV+Pembro shows an EFS, pCR and OS benefit compared to radical cystectomy alone. a Potential new SOC (again). cc: BioSpace biospace.com/press-releases…

Thanks for the time to discuss. This is an example that RWD support the use of intensified therapies for mHSPC—works just as well in all pts not just ‘trial-fit’ people!

JUST IN: IMvigor011 in muscle-invasive bladder cancer (MIBC) hits both DFS & OS with PD-L1 inhibitor Atezolizumab in ctDNA+ population. Major news for Precision Oncology in adjuvant Solid Cancers! Natera Tom Powles Roche natera.com/company/news/i…